ABC | Volume 112, Nº3, Março 2019

Comunicação Breve Ribeiro et al Efeito betabloqueador na oxidação de substratos durante o exercício na insuficiência cardíaca Arq Bras Cardiol. 2019; 112(3):304-308 1. Naegele M, Flammer AJ, Enseleit F, Ruschitzka F. Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments. Swiss MedWkly. 2016 Mar;146:w14295. 2. Ladage D, Schwinger RH, Brixius K. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther. 2013;31(2):76-83. 3. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26(3):615-29. 4. Smith J, Ferland A, Methot J, Brassard P, Lacroix S, Poirier P, et al. The beta-1 adrenergic antagonist, atenolol, decreases acylation stimulating protein, exercise capacity and plasma free fatty acids in men with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2012;22(6):495-502. 5. Blanchet M, Ducharme A, Racine N, Rouleau JL, Tardif JC, Juneau M, et al. Effects of cold exposure on submaximal exercise performance and adrenergic activation in patients with congestive heart failure and the effects of beta-adrenergic blockade (carvedilol or metoprolol). Am J Cardiol. 2003;92(5):548-53. 6. Ismail H, McFarlane JR, Nojoumian AH, Dieberg G, Smart NA. Clinical outcomes and cardiovascular responses to different exercise training intensities in patients with heart failure: a systematic review and meta- analysis. JACC Heart Fail. 2013;1(6):514-22. 7. Meyer P, Normandin E, GaydaM, BillonG, Guiraud T, Bosquet L, et al. High- intensity interval exercise in chronic heart failure: protocol optimization. J Card Fail. 2012;18(2):126-33. 8. Kraal JJ, Sartor F, Papini G, Stut W, Peek N, Kemps HM, et al. Energy expenditure estimation in beta-blocker-medicated cardiac patients by combining heart rate and body movement data. Eur Prev Cardiol. 2016;23(16):1734-42. 9. Ribeiro PA, Normandin E, Meyer P, Juneau M, Nigam A, Gayda M. Comparison of carbohydrate and lipid oxidation during different high- intensity interval exercise in patients with chronic heart failure. Am J Phys Med Rehabil. 2017;96(1):50-4. 10. Weir JB. Newmethods for calculating metabolic rate with special reference to protein metabolism. 1949. Nutrition. 1990;6(3):213-21. 11. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol Respir Environ Exerc Physiol. 1983;55(2):628-34. 12. Peronnet F, Massicotte D. Table of nonprotein respiratory quotient: an update. Can J Sport Sci 1991;16(1):23-9. 13. Beauvais F. [Physical training with beta-blockers in chronic heart failure]. Ann Cardiol Angeiol (Paris). 2010;59(4):229-33. 14. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14(4):489-94. 15. Gayda M, Normandin E, Meyer P, Juneau M, Nigam A. Comparison of carbohydrate and lipid oxidation during continuous and intermittent exercise in patients with chronic heart failure. Can J Cardiol. 2013;29(8):990-2. 16. Haykowsky MJ, Timmons MP, Kruger C, McNeely M, Taylor DA, Clark AM. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol. 2013;111(10):1466-9. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 308